Drug Profile
Research programme: pancreatic stem cell therapy - Microbot Medical
Latest Information Update: 13 Dec 2016
Price :
$50
*
At a glance
- Originator StemCells
- Class Stem cell therapies
- Mechanism of Action Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 1 diabetes mellitus
Most Recent Events
- 28 Nov 2016 StemCells has been acquired by Microbot Medical
- 19 Jul 2012 Development discontinued for Type-1 diabetes mellitus in USA before July 2012
- 08 May 2008 This programme is still in active development